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The mature epidermal growth factor receptor (EGFR) neither associates with nor requires the molecular chaperone heat-shock
protein 90 (Hsp90). Mutations in EGFR exons 18, 19, and 21 confer Hsp90 chaperone dependence. In non-small cell lung cancer
(NSCLC), these mutations are associated with enhanced sensitivity to EGFR inhibitors in vitro and with clinical response in vivo.
Although less prevalent, insertions in EGFR exon 20 have also been described in NSCLC. These mutations, however, confer
resistance to EGFR inhibitors. In NSCLC, exon 20 insertions have also been identified in the EGFR family member ErbB2. Here, we
examined the sensitivity of exon 20 insertion mutants to an Hsp90 inhibitor currently in the clinic. Our data demonstrate that both
EGFR and ErbB2 exon 20 insertion mutants retain dependence on Hsp90 for stability and downstream-signalling capability, and
remain highly sensitive to Hsp90 inhibition. Use of Hsp90 inhibitors should be considered in NSCLC harbouring exon 20 insertions in
either EGFR or ErbB2.
British Journal of Cancer (2007) 97, 741–744. doi:10.1038/sj.bjc.6603950 www.bjcancer.com
Published online 21 August 2007
& 2007 Cancer Research UK
Keywords: Hsp90; epidermal growth factor receptor mutation; ErbB2 mutation; kinase inhibition; non-small cell lung cancer
                                         
Both ErbB2 and epidermal growth factor receptor (EGFR) have
distinct requirements for heat-shock protein 90 (Hsp90). While the
nascent forms of both proteins require interaction with the
chaperone for proper maturation, only ErbB2 retains dependence
on Hsp90 at the plasma membrane (Xu et al, 2001, 2002). However,
Shimamura et al (2005) recently reported that certain EGFR kinase
domain mutations which occur in a sub-population of non-small
cell lung cancer (NSCLC) and which enhance sensitivity to EGFR
inhibitors, also conferred dependence on Hsp90 and resulted in
acquired sensitivity of the mature protein to Hsp90 inhibition.
These mutations include deletions in exon 19, and single amino-
acid substitutions in exons 18 and 21 (Lynch et al, 2004; Paez et al,
2004; Tsao et al, 2005). A smaller percentage of EGFR mutations
found in NSCLC (B9%) are insertions in exon 20 of EGFR (Kosaka
et al, 2004; Mitsudomi et al, 2005; Shigematsu et al, 2005a; Tam
et al, 2006). Of 1108 NSCLC patients examined, EGFR exon 20
insertions were identified in 1.6% (Greulich et al, 2005).
Importantly, however, in contrast to mutations in exons 18, 19,
and 21, exon 20 insertions render the EGFR resistant to inhibitors
such as gefitinib and erlotinib (Greulich et al, 2005). Likewise,
exon 20 insertions in the EGFR family member ErbB2 (found in
B2% of NSCLC) confer resistance to these drugs (Wang et al,
2006), making it imperative to identify alternative strategies to
inhibit the activity and signalling capability of these ErbB mutants
(Shimamura et al, 2006). To this end, we examined the Hsp90
association and dependence of several ErbB (EGFR and ErbB2)
exon 20 insertion mutants that have been identified in NSCLC.
MATERIALS AND METHODS
Cells, plasmid treatments, and western blotting
COS7 cells were maintained in a humidified atmosphere contain-
ing 5% CO2 in DMEM with 10% fetal bovine serum and antibiotics.
Exon 20 insertion mutations in EGFR were created by using the
QuickChange XL mutagenesis kit following the manufacturer’s
protocol (Stratagene, La Jolla, CA, USA). The primers used: for
EGFR/M766InsASV are CCTACGTGATGGCCAGCGTGGCCAGCG
TGGACAAC, reversed and complemented; for EGFR/N771InsPH
are GATGGCCAGCGTGGACAACCCCCACCCCCACGTGTGCCGC
CTGC, reversed and complemented; for EGFR/D770InsNPH are
GGCCAGCGTGGACAACCCCCACAACCCCCACGT, reversed and
complemented; for EGFR/D770InsNPG are GGCCAGCGTGGACA
ACCCCGGCAACCCCCACGT, reversed and complemented; and
for EGFR/V738InsKIPVAI are GAACCTGAGAAAGTTAAAATTC
CCGTCGCTATCAAAATTCCCGTCGC, reversed and complemen-
ted. COS7 cells were transfected with mutant EGFR constructs
using FuGene 6 (Roche Diagnostics, Indianapolis, IN, USA) and
following the manufacturer’s instructions. One day after transfec-
tion, cells were treated with/without 0.5mM 17-AAG (a kind gift
from Kosan Biosciences, Hayward, CA, USA) for 1h, and lysed
with TMNS (50mM Tris–HCl, pH 7.0, 20mM Na2MoO4, 0.09%
NP-40, 150mM NaCl) buffer supplemented with 20mgml
1 aprotinin,
20mgml
1 leupeptin, and 1mM PMSF. Epidermal growth factor
receptor proteins were immunoprecipitated with Ab-13 antibody
(Lab Vision, Freemont, CA, USA), separated by 4–20% gradient
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sSDS–PAGE, and transferred to PVDF (polyvinylidene fluoride)
membranes, which were probed sequentially for Hsp90 and
EGFR.
To examine effects of 17-AAG on stability, autophosphorylation,
and downstream signalling of EGFR exon 20 insertion mutants, we
transfected COS7 cells as indicated. Two days after transfection,
cells were treated with 0.5mM 17-AAG, 0.1mM gefitinib, or a
combination of the two drugs for 5h. Cells were lysed with
modified RIPA buffer (50mM Tris, pH 7.5, 1% NP40, 0.5% sodium
deoxycholate, 150mM NaCl, 1mM EDTA, 2mM sodium orthova-
nadate, 2mM NaF) supplemented with 8mM sodium orthovanadate
and protease inhibitors. Equivalent amounts of protein were
separated by 4–20% gradient SDS–PAGE and transferred to
nitrocellulose. Individual membranes were probed as indicated.
ErbB2 exon 20 insertion mutations were prepared using the
method described above. Primers used: for ErbB2/A771InsYVMA
are GAAGCATACGTGATGGCTTACGTGATGGCTGGTGTGGGCT
CCCCATATG, reversed and complemented; for ErbB2/V777InsGSP
are GCTGGTGTGGGCTCCCCAGGCTCCCCATATGTCTCCCGCCT
TCTGG, reversed and complemented. COS7 cells were transfected
as above with mutant ErbB2 constructs. One day after transfection,
cells were treated with/without 0.5mM 17-AAG for 1h, and lysed
with TMNS buffer supplemented with 20mgml
1 aprotinin,
20mgml
1 leupeptin, and 1mM PMSF. The ErbB2 proteins were
immunoprecipitated with Ab-5 antibody (Oncogene) and pro-
cessed as for EGFR analysis. In some cases, COS7 cells were treated
for 4h two days after transfection with 1mM 17-AAG. Cells were
lysed with modified RIPA buffer supplemented with 2mM sodium
orthovanadate and protease inhibitors. Equivalent amounts of
protein were separated by 4–20% gradient SDS–PAGE and
transferred to nitrocellulose. Individual membranes were probed
as indicated.
The NCI-H1781 NSCLC cells, harbouring a G776InsV_G/C in
exon 20 of ErbB2, were treated as above and association of Hsp90
before and after 17-AAG was monitored. The effect of 17-AAG on
the viability of NCI-H1781 cells was determined by monitoring
trypan blue exclusion on successive days using a Cellometer
AutoT4 (Nexcelom Bioscience, Lawrence, MA, USA). Determina-
tions were made in duplicate and data are expressed as a mean
percentage of viable cells in treated vs untreated cells at each time
point 7s.d.
RESULTS AND DISCUSSION
To date, no existing NSCLC cell line has been identified to
naturally express EGFR exon 20 insertion mutations. Therefore, to
study the Hsp90-dependence of EGFR exon 20 insertion mutants
we transiently transfected into COS7 cells four mutant EGFRs
(V738InsKIPVAI, M766InsASV, D770InsNPG, D770InsNPH) that
have been identified in tumour tissue of NSCLC patients. Twenty-
four hours later, cells were treated with 17-AAG, an Hsp90
inhibitor currently in multiple phase II clinical trials. In contrast to
transiently transfected wild-type EGFR, Hsp90 could be readily
coimmunoprecipitated with each of the mutant EGFRs, and this
association was remarkably sensitive to brief (1h) exposure of cells
to 17-AAG (0.5mM) (Figure 1A). Failure to detect Hsp90
association with mature wild-type EGFR in this experiment is
consistent with our earlier observation that, unlike mature ErbB2,
wild-type EGFR is resistant to Hsp90 inhibitor-induced degrada-
tion (Xu et al, 2001, 2005).
Next, we examined the effects of gefitinib and 17-AAG,
separately and together, on EGFR activation status and on
constitutive activation of the prosurvival Akt and Stat3 down-
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Figure 1 Exon 20 insertion mutations in EGFR confer interaction with and dependence on Hsp90. (A) Epidermal growth factor receptor exon 20
insertion mutants display 17-AAG-sensitive association with Hsp90. COS7 cells were transfected with wild type or mutant EGFR constructs as described in
Materials and Methods. One day after transfection, cells were treated with/without 0.5mM 17-AAG for 1h, and Hsp90 association with EGFR was monitored
by coimmunoprecipitation analysis. Membranes were probed sequentially for Hsp90 and EGFR as shown. (B) Stability, autophosphorylation, and
downstream signalling of EGFR exon 20 insertion mutants are inhibited by 17-AAG. Two days after transfection, COS7 cells were treated with 0.5mM
17-AAG, 0.1mM gefitinib, or a combination of the two drugs for 5h. Cells were lysed and processed as described in Materials and Methods. Individual
membranes were probed as indicated. The EGFR phosphorylation sites examined form docking sites linking the activated receptor to various downstream
effectors: EGFR/pY1068 associates with Grb2, Stat3/5, and Gab1; EGFR/pY1173 associates with Shp1 and Ptp1; EGFR/pY992 associates with PLCg and Shc;
and EGFR/pY1045 associates with Cbl. (C) A549 cells, expressing wild-type EGFR, were treated with 17-AAG as shown. Cells were lysed and processed as
described in Materials and Methods, and Western blots were probed as in (B) above.
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sstream-signalling pathways, previously shown to be key mediators
of mutant EGFR-dependent tumorigenesis (Greulich et al, 2005;
Jing and Tweardy, 2005; Uchida et al, 2007). Although not all exon
20 insertion mutants were equally active, their expression in COS7
cells led to equivalent upregulation of the steady-state phosphory-
lation of endogenous Akt and/or Stat3-signalling proteins
(Figure 1B). EGFR/D770insNPG, the most active mutant, was
insensitive to gefitinib (0.1mM, 5h), as were the less active mutants
EGFR/D770InsNPH and EGFR/M766InsASV. Surprisingly, the
activity of EGFR/V738InsKIPVAI was inhibited by gefitinib, as
was the activation status of both downstream effectors Akt and
Stat3. However, all four EGFR insertion mutants were quite
sensitive to 17-AAG (0.5mM, 5h), as the steady-state level of both
total and phosphorylated EGFR declined markedly after Hsp90
inhibitor treatment. The uniform downregulation of all autophos-
phorylated docking sites in EGFR suggests that Hsp90 inhibition
effectively uncouples the kinase from its various downstream-
signalling pathways (Schulze et al, 2005). In support of this
hypothesis, 17-AAG inhibited the activation of Akt and Stat3
independent of the particular EGFR insertion mutant under
examination, and with the possible exception of EGFR/V738In-
sKIPVAI, its activity did not appear to be additive with that of
gefitinib. For comparison, the effect of 17-AAG on wild-type
EGFR and several downstream-signalling pathways is shown in
Figure 1C. Stat3 phosphorylation remains sensitive to 17-AAG,
even in the absence of wild-type EGFR downregulation. From these
data, we conclude that EGFR exon 20 insertion mutants, even
though they resist inhibition by gefinitib, depend strongly on
association with Hsp90 for their stability and function. Brief
exposure to a clinically achievable concentration of 17-AAG
promoted rapid downregulation of their activity and the activity
of two important downstream-signalling pathways.
Unlike EGFR, mature wild-type ErbB2 depends on Hsp90
association for stability and, among client proteins of the
chaperone, ErbB2 is perhaps the most sensitive to Hsp90
inhibition (Chavany et al, 1996; Mimnaugh et al, 1996). Although
both ErbB2 and EGFR are highly homologous proteins, distinct
surface characteristics of a short loop in the N-lobe of the kinase
domain of both proteins determine Hsp90 binding and sensitivity
to 17-AAG (Xu et al, 2005). The ErbB2 exon 20 mutations result in
constitutive phosphorylation and activation of both ErbB2 and
EGFR and they confer resistance to clinically approved EGFR
tyrosine kinase inhibitors (Wang et al, 2006). As the amino acids
comprising this loop are encoded by nucleotides in exon 20, it was
of particular interest to determine if NSCLC ErbB2 exon 20
insertion mutants (found in B2% of NSCLC) acquired indepen-
dence from Hsp90 and resistance to 17-AAG. We examined three
naturally occurring ErbB2 insertion mutants (Stephens et al, 2004;
Shigematsu et al, 2005b; Buttitta et al, 2006; Willmore-Payne et al,
2006). Plasmids expressing either wild-type ErbB2, or the insertion
mutants ErbB2/A776InsYMVA or ErbB2/V777InsGSP (not found
in NSCLC cell lines) were transfected into COS7 cells and their
association with Hsp90 was examined (Figure 2A). Unexpectedly,
the two insertion mutants associated more strongly with Hsp90
than with wild-type ErbB2, but in each case brief exposure (1h)
to 17-AAG disrupted association with the chaperone. Functional
dependence of these insertion mutants on Hsp90 was further
supported by the marked sensitivity of total and phospho-ErbB2 to
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Figure 2 Exon 20 insertion mutations in ErbB2 do not abrogate association with or dependence on Hsp90. (A) ErbB2 exon 20 insertion mutants retain
17-AAG-sensitive association with Hsp90. The COS7 cells were transfected with wild-type or mutant ErbB2 constructs as shown. One day after
transfection, cells were treated with/without 0.5mM 17-AAG for 1h, and lysed as above. The appearance of Hsp90 in ErbB2 immunoprecipitates was
examined. (B) ErbB2 exon 20 insertion mutants retain sensitivity to Hsp90 inhibition. Two days after transfection, COS7cells were treated with 1mM
17-AAG for 4h. Cells were lysed and processed as described. Equivalent amounts of protein were separated by 4–20% gradient SDS–PAGE and
transferred to nitrocellulose. Individual membranes were probed as indicated. (C) NCI-H1781 NSCLC cells, harbouring a G776InsV_G/C in exon 20 of
ErbB2, were treated as above and association of Hsp90 before and after 17-AAG were monitored. (D) The effect of 17-AAG (0.5mM) on downstream
signalling (phospho-Akt and phospho-Stat3) in NCI-H1781 cells was examined as described above. (E) 17-AAG (0.5mM) promotes time-dependent loss of
viability of NCI-H1781 cells. Determinations were made in duplicate and data are expressed as a mean percentage of viable cells in treated vs untreated cells
at each time point 7s.d.
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sslightly longer exposure (4h) to 17-AAG (Figure 2B). The NSCLC
cell line NCI-H1781 naturally expresses an ErbB2 protein carrying
a G776InsV_G/C mutation in exon 20 (Shimamura et al, 2006; a
mutation previously identified in a number of NSCLC adenocarci-
nomas). Endogenous mutant ErbB2 in NCI-H1781 coimmuno-
precipitated with Hsp90 and this association was disrupted by
17-AAG (Figure 2C). Further, analogous to our earlier data
examining downstream signalling from EGFR exon 20 insertion
mutants, 17-AAG strongly suppressed Akt- and Stat3-signalling
pathways in NCI-H1781 cells, concomitant with loss of ErbB2
protein (Figure 2D). Finally, we observed a time-dependent loss of
cell viability following exposure of these cells to 17-AAG
(Figure 2E); this is the expected outcome if NCI-H1781 cells were
‘addicted’ to this ErbB2 insertion mutant, as has been previously
suggested (Shimamura et al, 2006).
Non-small cell lung cancer expressing EGFR and ErbB2 exon 20
insertion mutants have proven resistant to currently approved
EGFR tyrosine kinase inhibitors. Preliminary clinical data
suggest that 17-AAG, which is well-tolerated in vivo, displays
activity in the context of ErbB2-positive metastatic breast
cancer (Modi et al, 2005). Further, Shimamura et al (2005)
have shown recently that EGFR exon 19 deletion mutants, exons
18 and 21 substitution mutants, and exon 20 T790M point
mutants all require Hsp90 and are sensitive to chaperone
inhibition. In light of these data and our current findings, we
suggest that 17-AAG, or other Hsp90 inhibitor, should be
considered as a viable therapeutic alternative in all instances
of EGFR and ErbB2 kinase domain mutation, including the 3–4%
of NSCLC that express exon 20 insertions in either of these
proteins.
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